These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 16264795)

  • 1. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intergroup Exemestane Study mature analysis: overall survival data.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New stars in the sky of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
    Aapro M
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
    Jones SE
    Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S41-4. PubMed ID: 16595025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New options in adjuvant endocrine therapy in breast cancer].
    Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
    Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.